329 related articles for article (PubMed ID: 26305052)
1. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescents - rationale and protocol.
Wicklow B; Wittmeier K; T' Jong GW; McGavock J; Robert M; Duhamel T; Dolinsky VW
Biochem Cell Biol; 2015 Oct; 93(5):522-30. PubMed ID: 26305052
[TBL] [Abstract][Full Text] [Related]
2. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Faghihzadeh F; Adibi P; Hekmatdoost A
Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
Chachay VS; Macdonald GA; Martin JH; Whitehead JP; O'Moore-Sullivan TM; Lee P; Franklin M; Klein K; Taylor PJ; Ferguson M; Coombes JS; Thomas GP; Cowin GJ; Kirkpatrick CM; Prins JB; Hickman IJ
Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2092-103.e1-6. PubMed ID: 24582567
[TBL] [Abstract][Full Text] [Related]
4. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
Barchetta I; Del Ben M; Angelico F; Di Martino M; Fraioli A; La Torre G; Saulle R; Perri L; Morini S; Tiberti C; Bertoccini L; Cimini FA; Panimolle F; Catalano C; Baroni MG; Cavallo MG
BMC Med; 2016 Jun; 14():92. PubMed ID: 27353492
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
Chen S; Zhao X; Ran L; Wan J; Wang X; Qin Y; Shu F; Gao Y; Yuan L; Zhang Q; Mi M
Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.
Heebøll S; Kreuzfeldt M; Hamilton-Dutoit S; Kjær Poulsen M; Stødkilde-Jørgensen H; Møller HJ; Jessen N; Thorsen K; Kristina Hellberg Y; Bønløkke Pedersen S; Grønbæk H
Scand J Gastroenterol; 2016; 51(4):456-64. PubMed ID: 26784973
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
[TBL] [Abstract][Full Text] [Related]
8. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
[TBL] [Abstract][Full Text] [Related]
9. Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis.
Abeysekera KWM; Orr JG; Gordon FH; Howe LD; Hamilton-Shield J; Heron J; Hickman M
BMC Gastroenterol; 2022 Jun; 22(1):323. PubMed ID: 35773644
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Zinc Supplementation on Steatosis Severity and Liver Function Enzymes in Overweight/Obese Patients with Mild to Moderate Non-alcoholic Fatty Liver Following Calorie-Restricted Diet: a Double-Blind, Randomized Placebo-Controlled Trial.
Fathi M; Alavinejad P; Haidari Z; Amani R
Biol Trace Elem Res; 2020 Oct; 197(2):394-404. PubMed ID: 32020523
[TBL] [Abstract][Full Text] [Related]
11. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial.
Kantartzis K; Fritsche L; Bombrich M; Machann J; Schick F; Staiger H; Kunz I; Schoop R; Lehn-Stefan A; Heni M; Peter A; Fritsche A; Häring HU; Stefan N
Diabetes Obes Metab; 2018 Jul; 20(7):1793-1797. PubMed ID: 29484808
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol.
Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
BMJ Open; 2017 Jul; 7(7):e016914. PubMed ID: 28698350
[TBL] [Abstract][Full Text] [Related]
13. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
[TBL] [Abstract][Full Text] [Related]
14. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M
Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703
[TBL] [Abstract][Full Text] [Related]
15. Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial.
Ali Sangouni A; Abdollahi S; Mozaffari-Khosravi H
BMC Cardiovasc Disord; 2022 May; 22(1):212. PubMed ID: 35538431
[TBL] [Abstract][Full Text] [Related]
16. The anti-anginal ranolazine does not confer beneficial actions against hepatic steatosis in male mice subjected to high-fat diet and streptozotocin-induced type 2 diabetes.
Saed CT; Greenwell AA; Tabatabaei Dakhili SA; Gopal K; Eaton F; Ussher JR
Can J Physiol Pharmacol; 2022 May; 100(5):393-401. PubMed ID: 34851748
[TBL] [Abstract][Full Text] [Related]
17. Effects of an exercise program on hepatic metabolism, hepatic fat, and cardiovascular health in overweight/obese adolescents from Bogotá, Colombia (the HEPAFIT study): study protocol for a randomized controlled trial.
González-Ruíz K; Correa-Bautista JE; Izquierdo M; García-Hermoso A; Dominguez-Sanchez MA; Bustos-Cruz RH; García-Prieto JC; Martínez-Vizcaíno V; Lobelo F; González-Jiménez E; Prieto-Benavides DH; Tordecilla-Sanders A; Schmidt-RioValle J; Perez G; Ramírez-Vélez R
Trials; 2018 Jun; 19(1):330. PubMed ID: 29941024
[TBL] [Abstract][Full Text] [Related]
18. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease.
Boyraz M; Pirgon Ö; Dündar B; Çekmez F; Hatipoğlu N
J Clin Res Pediatr Endocrinol; 2015 Jun; 7(2):121-7. PubMed ID: 26316434
[TBL] [Abstract][Full Text] [Related]
20. Effects of polyphenol supplementation on hepatic steatosis, intima-media thickness and non-invasive vascular elastography in obese adolescents: a pilot study protocol.
Moretti JB; Drouin A; Truong C; Youn E; Cloutier A; Alvarez F; Paganelli M; Grzywacz K; Jantchou P; Dubois J; Levy E; El Jalbout R
BMJ Open; 2024 Jan; 14(1):e074882. PubMed ID: 38296273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
